Prognostic Value of a Trifecta for Predicting Survival Outcomes After Radical Cystectomy: A Large-Scale Multicenter Study
Purpose: This study aimed to evaluate the prognostic value of a trifecta, defined as negative soft tissue surgical margin (STSM), removal of ≥16 lymph nodes, and absence of major complications (Clavien-Dindo classification grade >III) within 90 days, after radical cystectomy (RC), using a large multicenter cohort.Materials and Methods: We retrospectively analyzed data from 3,972 patients with bladder cancer who underwent RC at 11 tertiary centers in South Korea between 2003 and 2024. Survival outcomes, including overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS), were compared according to trifecta status using Kaplan-Meier and Cox regression analyses. Propensity score matching was performed to adjust for baseline differences.Results: A total of 2,014 eligible patients were included in the final analysis, and the trifecta was achieved in 47.8%. Kaplan-Meier analysis demonstrated significantly improved 5- and 10-year OS (66.7% vs. 62.0%; 62.9% vs. 57.2%; p=0.002), CSS (79.3% vs. 75.4%; 77.8% vs. 73.8%; p=0.008), and RFS (62.7% vs. 57.6%; 60.8% vs. 55.2%; p=0.001) in the trifecta group. In multivariable analysis, trifecta achievement was significantly associated with better OS (HR, 0.813; p=0.008), CSS (HR, 0.787; p=0.017), and RFS (HR, 0.844; p=0.036). Among individual components, negative STSM showed the strongest prognostic effect across all endpoints.Conclusions: In this large multicenter study, patients who achieved the RC trifecta exhibited significantly superior survival outcomes compared with those who did not. The trifecta may serve as a practical and standardized metric for assessing surgical quality and performance in RC. Future prospective studies are warranted to validate its prognostic and quality-assurance utility.
Authors
- Bumjin Lim (ORCID: https://orcid.org/0000-0002-1746-6072)
- Tae Gyun Kwon (ORCID: https://orcid.org/0000-0002-4390-0952)
- Wan Song (ORCID: https://orcid.org/0000-0003-0971-1805)
- Ji Eun Heo (ORCID: https://orcid.org/0000-0002-4184-8468)
- Ja Hyeon Ku (ORCID: https://orcid.org/0000-0002-0391-2342)
- Byong Chang Jeong (ORCID: https://orcid.org/0000-0002-5399-2184)
- Geehyun Song (ORCID: https://orcid.org/0000-0001-7486-4520)
- Sung Gu Kang (ORCID: https://orcid.org/0000-0001-5791-5410)
- Kyung Hwan Kim (ORCID: https://orcid.org/0000-0001-7162-6527)
- Seung‐hwan Jeong (ORCID: https://orcid.org/0000-0002-8076-3643)
- Hyun Hwan Sung (ORCID: https://orcid.org/0000-0001-9845-3742)
- Jong Jin Oh (ORCID: https://orcid.org/0000-0003-0448-5992)
- Ho Kyung Seo (ORCID: https://orcid.org/0000-0003-2601-1093)
- Jong Ho Park (ORCID: https://orcid.org/0009-0004-2332-0012)
- Jong Kil Nam (ORCID: https://orcid.org/0000-0002-3424-2417)
- Seok Ho Kang (ORCID: https://orcid.org/0000-0002-1524-5233)
- Bumsik Hong (ORCID: https://orcid.org/0000-0003-1991-1229)
- Won Sik Ham (ORCID: https://orcid.org/0000-0003-2246-8838)
- Wook Nam (ORCID: https://orcid.org/0000-0002-1424-9339)
- Tae‐Hwan Kim (ORCID: https://orcid.org/0000-0003-4924-4826)
- Sangchul Lee (ORCID: https://orcid.org/0000-0003-0844-6843)
Publication Details
- Journal
- Journal of Urologic Oncology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.22465/juo.255000820041
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00